Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience

Clinical Transplantation

Volumn 30, Issue 6, 2016, Pages 709-713

  Jackson, Whitney E ^a   Hanouneh, Mohamad ^a   Apfel, Tehilla ^a   Alkhouri, Naim ^a   John, Binu V ^a   Zervos, Xaralambos ^b   Zein, Nizar N ^a   Hanouneh, Ibrahim A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

Author keywords

hepatitis C virus; liver transplantation; simeprevir; sofosbuvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN; CYTOCHROME P450 3A; EVEROLIMUS; HEMOGLOBIN; MYCOPHENOLATE MOFETIL; PREDNISONE; RAPAMYCIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; VIRUS RNA; ANTIVIRUS AGENT;

ACUTE KIDNEY FAILURE; ADULT; ANTIVIRAL THERAPY; ARTICLE; CHOLANGITIS; CHOLESTATIC HEPATITIS; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FIBROSING CHOLESTATIC HEPATITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEADACHE; HEPATIC ARTERY THROMBOSIS; HEPATITIS C; HEPATITIS C GENOTYPE 1 INFECTION; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INTENTION TO TREAT ANALYSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MYALGIA; OSTEOMYELITIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RECURRENT INFECTION; SEPSIS; SIDE EFFECT; SUSTAINED VIROLOGIC RESPONSE; TIME TO TREATMENT; TREATMENT DURATION; ADOLESCENT; ADVERSE EFFECTS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; GENETICS; GENOTYPE; HEPACIVIRUS; ISOLATION AND PURIFICATION; PATHOLOGY; PROSPECTIVE STUDY; RECURRENT DISEASE; RETROSPECTIVE STUDY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85010662203     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12738     Document Type: Article

References (25)

1. Wright TL, Donegan E, Hsu HH et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992: 103: 317.
2. Dickson RC, Caldwell SH, Ishitani MB et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation 1996: 61: 701.
3. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl 2002: 8(10 Suppl 1): S14.
4. Garcia-Retortillo M, Forns X, Feliu A et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002: 35: 680.
5. Butt AA, Yan P, Lo Re V 3rd et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015: 175: 178.
6. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000: 132: 296.
7. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008: 48: 418.
8. Dienstag JL, Ghany MG, Morgan TR et al. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011: 54: 396.
9. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002: 122: 889.
10. Gurusamy KS, Tsochatzis E, Toon CD, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2013: 12: CD006573.
11. Bzowej N, Nelson DR, Terrault NA et al. PHOENIX: a randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011: 17: 528.
12. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013: 19: 837.
13. Hunt D, Pockros P. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? Curr Gastroenterol Rep 2013: 15: 303.
14. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013: 368: 1878.
15. Jacobson IM, Dore GJ, Foster GR et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014: 384: 403.
16. Lawitz E, Sulkowski MS, Ghalib R et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014b: 384: 1756.
17. Pungpapong S, Aqel B, Leise M et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology 2015: 61: 1880.
18. Gutierrez JA, Carrion AF, Avalos D et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl 2015: 21: 823.
19. Khemichian S, Lee B, Kahn J et al. Sofosbuvir and simeprevir therapy for recurrent hepatitis C infection after liver transplantation. Transplant Direct 2015: 1: 1.
20. Punzalan CS, Barry C, Zacharias I et al. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant 2015: 29: 1105.
21. Saab S, Greenberg A, Li E et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int 2015: 35: 2442.
22. Brown RS Jr, O'Leary JG, Reddy KR et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. Liver Transpl 2016: 22: 24.
23. Moreira RK, Salomao M, Verna EC, Brown RS Jr, Lefkowitch JH. The Hepatitis Aggressiveness Score (HAS): a novel classification system for post-liver transplantation recurrent hepatitis C. Am J Surg Pathol 2013: 37: 104.
24. Verna EC, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS Jr. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl 2013: 19: 78.
25. https://www.olysio.com/shared/product/olysio/prescribing-information.pdf (accessed December 2015).